Session Details
[S13]How to continuously develop globally acceptable "Made in Japan" drugs?
Thu. Mar 26, 2020 4:15 PM - 6:15 PM JST
Thu. Mar 26, 2020 7:15 AM - 9:15 AM UTC
Thu. Mar 26, 2020 7:15 AM - 9:15 AM UTC
[Room B] Room B-1 2F
Organizers: Takeshi Suzuki (Keio Univ, Fac Pharm), Hiroshi Nakamura (Keio Buis Sch)
In recent times, many Japanese industries are not able to overcome the effects of the recession (for example, car manufacturers, electronic device companies, etc.). However, pharmaceutical industries have been able to maintain their financial interests even after the Lehman-shock years.
Japan is one of the countries in the word that has much potential for developing new, useful drugs. However, the number of well-known "Made in Japan" drugs known globally and sold abroad is very small. One reason for such a weakness in the Japanese pharmaceutical industry is the specificity of characteristics comprising the pharmaceutical market in Japan with regard to other counties, particularly the US. Since pharmaceutical industries in Japan depend primarily on domestic sales, they focus on domestic needs for drug development.
The theme of this symposium is how to continuously develop globally acceptable "Made in Japan" drugs. Four speakers, with different specialties, discuss how drug development can be promoted in Japan. This is an important opportunity for discussing the business side of pharmaceutics at the Pharmaceutical Society of Japan meeting.
Japan is one of the countries in the word that has much potential for developing new, useful drugs. However, the number of well-known "Made in Japan" drugs known globally and sold abroad is very small. One reason for such a weakness in the Japanese pharmaceutical industry is the specificity of characteristics comprising the pharmaceutical market in Japan with regard to other counties, particularly the US. Since pharmaceutical industries in Japan depend primarily on domestic sales, they focus on domestic needs for drug development.
The theme of this symposium is how to continuously develop globally acceptable "Made in Japan" drugs. Four speakers, with different specialties, discuss how drug development can be promoted in Japan. This is an important opportunity for discussing the business side of pharmaceutics at the Pharmaceutical Society of Japan meeting.
[S13-1]Analysis from multiple viewpoints to identify the unique characteristics of the Japanese drug market.
○Takeshi Suzuki1 (1. Keio Univ, Fac Pharm)
[S13-2]Future prospects for drug discovery innovation and the pharmaceutical industry.
○Hiroaki Hashimoto1 (1. Nikkei Business Publications, Inc.)
[S13-3]The past, present, and future of Japan-based pharma industry, dilemma over how to find its growth scenario.
○Naoto Murakami1 (1. Office of Pharmaceutical Industry Research, Japan Pharmaceutical Manufacturers Association)
[S13-4]Future vision of the domestic pharmaceutical industry in Japan from the viewpoint of directions of the drug pricing system and cost-effectiveness evaluation.
○Hiroshi Nakamura1 (1. Keio Univ, Keio Business School)